TRPM3-Induced Gene Transcription Is under Epigenetic Control

Gerald Thiel * and Oliver G. Rössler

Department of Medical Biochemistry and Molecular Biology, Saarland University, Building 44, 66421 Homburg, Germany; oliver.roessler@uks.eu
* Correspondence: gerald.thiel@uks.eu; Tel.: +49-684-1162-6506

Abstract: Transient receptor potential M3 (TRPM3) cation channels regulate numerous biological functions, including gene transcription. Stimulation of TRPM3 channels with pregnenolone sulfate activates stimulus-responsive transcription factors, which bind to short cognate sequences in the promoters of their target genes. In addition, coregulator proteins are involved that convert the chromatin into a configuration that is permissive for gene transcription. In this study, we determined whether TRPM3-induced gene transcription requires coactivators that change the acetylation pattern of histones. We used compound A485, a specific inhibitor of the histone acetyltransferases CBP and p300. In addition, the role of bromodomain proteins that bind to acetylated lysine residues of histones was analyzed. We used JQ1, an inhibitor of bromodomain and extra terminal domain (BET) family proteins. The results show that both compounds attenuated the activation of AP-1 and CREB-regulated gene transcription following stimulation of TRPM3 channels. Inhibition of CBP/p300 and BET proteins additionally reduced the transcriptional activation potential of the transcription factors c-Fos and Elk-1. Transcriptional upregulation of the interleukin-8 gene was attenuated by A485 and JQ1, indicating that proinflammatory cytokine expression is controlled by CBP/p300 and bromodomain proteins. We conclude that TRPM3-induced signaling involves transcriptional coactivators and acetyl-lysine-bound bromodomain proteins for activating gene transcription.

Keywords: AP-1; A485; BET proteins; bromodomain; Elk-1; interleukin-8; JQ1; CREB; TRPM3

1. Introduction

TRPM3 (Transient receptor potential M3) channels are nonselective cation channels that can be activated with the neurosteroid pregnenolone sulfate [1,2]. Numerous biological functions are associated with TRPM3 activation, including temperature and pain sensation, insulin secretion, contraction of vascular smooth muscles, and tumorigenesis [3]. In the somatosensory system, TRPM3 functions as a thermosensor and chemosensor. Analysis of transgenic mice that did not express TRPM3 revealed that the animals did not respond adequately to noxious heat [4]. Genetic experiments revealed that perception of acute noxious heat sensing requires TRPM3, as well as TRPA1 and TRPV1 [5]. In addition, transcription mediated by AP-1, c-Jun, c-Fos, Elk-1 and Egr-1 is induced as a result of TRPM3 stimulation [2,3,6]. These stimulus-responsive transcription factors interact with the regulatory regions of their target genes, resulting in enhanced transcription. The gene products of these target genes contribute to the physiological and biochemical alterations observed after TRPM3 stimulation. We have recently shown that TRPM3-induced activation AP-1 stimulates transcription of the delayed response gene encoding the cytokine interleukin-8 [7]. The expression of interleukin-8 could lead to inflammatory changes as a consequence of TRPM3 stimulation.

The signaling cascade triggered by stimulation of TRPM3 channels leads to binding of stimulus-activated transcription factors to short DNA sequences in the promoters of their target genes. In addition, transcription factors interact with numerous coregulator proteins to decompact repressive chromatin structures. Chromatin comprises DNA complexed with histone proteins. The DNA packaging in chromatin is essential for gene transcription.
because the chromatin can be compact so that transcriptional regulators cannot bind to
the DNA, or it can have an open configuration that allows interactions between DNA
and transcription factors and recruitment of RNA polymerase II to DNA. Transcriptional
activators bind to various coregulator proteins that either function as chromatin-modifying
enzymes or are part of ATP-dependent protein complexes that modulate the chromatin
status. The architecture of the chromatin is modified by enzymes that transfer or remove
post-translational modifications of histones. One important modification is acetylation [8,9].
Histone acetyltransferases catalyze the acetylation of lysine residues of histones 3 and 4.
Acetylation of histones reduces positive charges, thereby reducing the interaction between
DNA and histone proteins. As a result, chromatin converts to an open configuration favorable
for gene transcription [10]. Moreover, acetylated histones are binding sites for numerous
proteins that specifically interact through their bromodomain with acetylated histones [11,12].
Conversely, deacetylation of histones, catalyzed by histone deacetylases, leads to chromatin
compaction, and this enzymatic reaction is connected with transcriptional repression.

Here, we investigated whether TRPM3-induced gene transcription depends on the
recruitment and biological activity of coactivators that change the acetylation pattern of
histones. We used a pharmacological approach to inhibit the histone acetyltransferase
activities of the paralogs CBP (CREB-binding protein) and p300. Both proteins are master
regulators of gene transcription that interact with numerous transcription factors and mod-
ify their activities [13–15]. In addition, we pharmacologically blocked bromodomain and
extra terminal domain (BET) protein interactions with acetylated histones. The results show
that epigenetic regulatory proteins such as CBP/p300 and BET proteins are required for
TRPM3 channel-mediated gene transcription, indicating that TRPM3-induced transcription
is under epigenetic control.

2. Results

2.1. CBP/p300 and Bromodomain and Extra-Terminal (BET) Inhibitors Attenuate TRPM3-Induced
Activation of AP-1

Pharmacological and genetic experiments have shown that stimulation of TRPM3
induces transcription mediated by the transcription factor activator protein AP-1 [2,3,6]. We
therefore investigated whether pharmacological inhibition of CBP/p300, and subsequent
disruption of histone acetyltransferase activity, attenuates AP-1 activation as a result of
TRPM3 channel stimulation. Figure 1A shows the modular structure of CBP.

There are several methods to measure stimulus-induced gene transcription, including
measurement of nuclear translocation of transcription factors, measurement of transcription
factor expression levels, phosphorylation, or DNA binding. The most reliable method to
detect and quantify stimulus-induced transcription factor activation is to use a transcription
factor-responsive reporter gene embedded in chromatin that allows direct measurement of
transcriptional activation [16]. The reporter gene must be implanted into the chromatin
of the cells to ensure that the reporter genes are packed into an ordered nucleosomal
structure. The Coll.luc reporter gene was used as a sensor to measure AP-1 activity
(Figure 2A) [16]. The reporter gene was integrated into the chromatin via lentiviral gene
transfer. This approach was the prerequisite for analyzing epigenetic gene regulation
following stimulation of TRPM3 channels. T-REx-TRPM3 cells were used as a cellular
model system. In these cells, the addition of tetracycline to the culture medium induces
TRPM3 biosynthesis, as shown previously [2]. TRPM3 channels are able to activate voltage-
gated Ca\(^{2+}\) channels [3] which are not expressed in T-REx-TRPM3 cells [17]. We therefore
avoided an interference between TRPM3 and voltage-gated Ca\(^{2+}\) channel. We infected T-
REx-TRPM3 cells with a Coll.luc-containing lentivirus and maintained the cells in a medium
containing tetracycline to induce the expression of TRPM3. Cells were cultured in the serum-reduced medium for 24 h and preincubated with the potent and selective CBP/p300
histone acetyltransferase inhibitor A485 (Figure 1B). The results show that the presence of A485
attenuated the TRPM3-mediated activation of AP-1. AP-1 activity was reduced by more than
80% when we incubated T-REx-TRPM3 cells with the histone acetyltransferase inhibitor A485
(Figure 2B). Next, we used the compound JQ1 (Figure 1D), a thieno-triazolo-1,4-diazepine that functions as an inhibitor of BET proteins. JQ1 binds competitively to the bromodomains of BET proteins and displaces these proteins from chromatin [18]. The modular structure of two BET proteins, BRD3 and BRD4, is depicted in Figure 1C. The presence of the bromodomain inhibitor JQ1 in the culture medium resulted in an 80% reduction of AP-1 activity in stimulated T-REx-TRPM3 cells. Thus, stimulation of AP-1 following TRPM3 activation is controlled by the coactivators CBP/p300 and the BET acetyl-lysine binding proteins.

**Figure 1.** Pharmacological inhibitors of epigenetic gene regulation. (A) Modular structure of the transcriptional coactivator and acetyltransferase CBP. The paralog p300 has a similar modular structure. Both proteins have a nuclear receptor interaction domain (NRID), two transcriptional adapter zinc finger domains (TAZ), a kinase inducible domain interacting domain (KIX) that binds CREB, the CREB-related protein ATF-1, c-Jun and other transcription factors, a bromodomain, a PHD-RING module, and a histone acetyltransferase (HAT) domain. The C-terminal TAZ domain binds c-Fos. (B) Chemical structure of the CBP/p300 catalytic inhibitor A485. (C) Modular structure of the BET proteins BRD3 and BRD4. BET proteins have two bromodomains (BD) as well as an extra-terminal (ET) domain that functions as a protein binding module for other chromatin-modifying proteins. BRD4 contains additionally a C-terminal domain (CTD) that functions as a binding site for P-TEFb (positive transcription elongation factor b). (D) Chemical structure of the pan-BET-inhibitor JQ1.
Figure 2. Pharmacological inhibition of CBP/p300 and BET proteins attenuates TRPM3-mediated activation of AP-1. (A) Provirus containing the Coll.luc (collagenase promoter/luciferase) reporter gene. The AP-1 DNA binding site (known as 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element (TRE)) is indicated. The provirus contains a deletion within the 5′LTR U3 region. Additionally, the provirus contains the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) and the HIV flap element. (B,C) T-REx-TRPM3 cells were infected with a Coll.luc-containing recombinant lentivirus. Cells were incubated in a serum-reduced medium for 24 h that was supplemented with tetracycline (1 µg/mL) to induce TRPM3 expression. Preincubation of the cells was performed for 3 h with either the histone acetyltransferase inhibitor A485 (3 µM) (B), or the BET inhibitor JQ1 (0.5 µM) (C). T-REx-TRPM3 cells were stimulated for 24 h with pregnenolone sulfate (PregS, 20 µM) in the presence of the inhibitor. Cell extracts were prepared and analyzed for luciferase activities. Luciferase activity was normalized to the protein concentration. Data shown are mean ± SD of four (B) or three (C) independent experiments performed in quadruplicate (**p < 0.001).
2.2. Inhibitors of CBP/p300 and BET Proteins Reduce the TRPM3-Mediated Stimulation of the Interleukin-8 (IL-8) Promoter

To confirm the observation that the TRPM3-mediated stimulation of AP-1 is controlled by CBP/p300 and BET proteins, we analyzed the transcription of a recently identified target gene of AP-1, the gene encoding the cytokine interleukin-8 (IL-8). Stimulation of TRPM3 channels activates IL-8 gene transcription and required the AP-1 binding found in the proximal IL-8 gene promoter [7]. We integrated the IL-8.luc reporter gene into the chromatin of T-REx-TRPM3 cells. Transcription of the reporter gene was driven by the IL-8 promoter (sequence −1481 to +44) (Figure 3A). Tetracycline-treated T-REx-TRPM3 cells were stimulated with pregnenolone sulfate. In addition, we added either A485 or JQ1 to the culture medium. Inhibition of CBP/p300 activity reduced IL-8 promoter-controlled gene transcription by 61% (A485, Figure 3B), whereas incubation of T-REx-TRPM3 cells with the compound JQ1 reduced IL-8 promoter activity by more than 80% (JQ1, Figure 3C).

![Figure 3A](https://example.com/figure3a.png)

**Figure 3.** Pharmacological inhibition of CBP/p300 and BET proteins attenuates interleukin-8 promoter activity following stimulation of TRPM3 channels. (A) Provirus containing the IL-8.luc reporter gene, encompassing IL-8 gene sequences from −1481 to +44. (B,C) T-REx-TRPM3 cells were infected with a recombinant lentivirus containing the IL-8.luc reporter gene. The cells were treated, stimulated, harvested, and analyzed as described in the legend in Figure 2. Data shown are mean ± SD of four (B) or three (C) independent experiments performed in quadruplicate (*** p < 0.001).
2.3. The Transcriptional Activation Potential of the Transcription Factor c-Fos Was Reduced by CBP/p300 and BET Protein Inhibitors in Stimulated T-REx-TRPM3 Cells

Proteins of the transcription factor families Jun, Fos, and ATF form the dimeric AP-1 complex. These proteins possess a leucine zipper domain for dimerization. Stimulation of TRPM3 channels activates the c-Fos promoter and increases the biological activity of c-Fos [3]. We investigated whether the presence of either the CBP/p300 inhibitor A485 or the BET protein inhibitor JQ1 changes the biological activity of c-Fos. The transcriptional activation potential, i.e., the biological activity of c-Fos, was measured in T-REx-TRPM3 cells expressing a GAL4-c-Fos fusion protein (Figure 4A). The DNA interaction domain of GAL4 binds to a reporter gene that contained binding sites for GAL4 (UAS, upstream regulatory sequence) in its regulatory region (Figure 4B). T-REx-TRPM3 cells were infected with a lentivirus containing the reporter gene UAS5Sp1luc. T-REx-TRPM3 cells were additionally infected with a lentivirus encoding the GAL4-c-Fos fusion protein. The infected cells were incubated in serum-reduced and tetracycline-supplemented medium and stimulated with pregnenolone sulfate. The compounds A485 or JQ1 were added as indicated. Figure 4C shows that inhibition of CBP/p300 acetyltransferase activity by A485 completely blocked the biological activity of c-Fos. Inhibition of BET protein interaction with acetylated lysine residues reduced the transcriptional activation potential of c-Fos by 76% (JQ1, Figure 4D).

Figure 4. Pharmacological inhibition of CBP/p300 and BET proteins attenuates TRPM3-induced up-regulation of the transcriptional activation potential of c-Fos. (A) The modular structure of the GAL4-c-Fos fusion protein. (B) Provirus that encodes the GAL4-responsive reporter gene UAS5Sp1luc.
(C,D) T-REx-TRPM3 cells were infected with a UAS5Sp12.luc containing lentivirus. T-REx-TRPM3 cells were infected with a second lentivirus that encoded for the GAL4-c-Fos protein. The cells were maintained in the serum-reduced medium in the presence of tetracycline for 24 h. T-REx-TRPM3 cells were stimulated with pregnenolone sulfate (PregS, 20 µM) for 24 h in the presence or absence of A485 (3 µM) (C), or JQ1 (0.5 µM) (D). Cells were harvested and analyzed as described in the legend to Figure 2 ((C), n = 6; (D), n = 3; *** p < 0.001).

2.4. The Transcriptional Activation Potential of the Ternary Complex Factor Elk-1 Is Reduced in the Presence of Either CBP/p300 or BET Protein Inhibitors in Stimulated T-REx-TRPM3 Cells

The ternary complex factor Elk-1 controls c-Fos expression and in this way regulates AP-1 activity [2,6]. We therefore investigated whether the biological activity of Elk-1 is changed in the presence of CBP/p300 or the BET protein inhibitors. We used a GAL4-Elk-1 fusion protein (Figure 5A) to measure the transcriptional activation potential of Elk-1. Elk-1 activity is regulated by phosphorylation, mediated by a phosphorylation-responsive activation domain within the Elk-1 protein. This activation domain is fused to the DNA binding domain of GAL4. GAL4-Elk-1 was expressed in T-REx-TRPM3 cells containing the GAL4-responsive reporter gene UAS5Sp12.luc. Figure 5B shows that TRPM3-mediated activation of Elk-1 was reduced by 88% when cells were incubated with A485. The transcriptional activation potential of Elk-1 was reduced by 76% with compound JQ1 in stimulated T-REx-TRPM3 cells (Figure 5C).

![Figure 5](image-url)

Figure 5. CBP/p300 and BET inhibitors reduce the transcriptional activation potential of Elk-1 in stimulated T-REx-TRPM3 cells. (A) Domain structure of GAL4-Elk-1 (B,C) T-REx-TRPM3 cells were
infected with a lentivirus containing the UAS^Sp1^2.luc reporter gene. Cells were infected with a second lentivirus that encoded for the GAL4-Elk-1 fusion protein. T-REx-TRPM3 cells were maintained in serum-reduced and tetracyclin-supplemented medium for 24 h. Stimulation was performed with pregnenolone sulfate (PregS, 20 µM) for 24 h. Addition of either A485 (3 µM) (B) or JQ1 (0.5 µM) (C) is indicated. Cells were harvested and analyzed as described in the legend to Figure 2 (n = 3; *** p < 0.001).

2.5. Measurement of cAMP Response Element-Mediated Mediated Transcription Using a CRE-Containing Reporter Gene and a CREB Mutant

CBP was discovered as a co-activator of CREB (cAMP response element (CRE) binding protein) that regulates CREB-mediated transcription. Soon after, a similar activity was detected for p300 [19,20]. We therefore sought to determine whether stimulation of TRPM3 activates CREB, and if this is the case, whether CBP and p300 control transcription via CRE following stimulation of TRPM3 channels. To measure CRE-mediated transcription we used the c-FosCRE^4.luc reporter gene, which contains four copies of CRE derived from the c-Fos gene in its regulatory region (Figure 6A). To demonstrate the functionality of this reporter gene, a constitutively active CREB mutant, C2/CREB, was expressed in T-REx-TRPM3 cells. The domain structures of CREB, CREB2 and C2/CREB are shown in Figure 6B. C2/CREB contains the phosphorylation-independent activation domain of CREB2. Expression of C2/CREB in T-REx-TRPM3 cells resulted in a significant upregulation of CRE-mediated transcription (Figure 6C), indicating that the reporter gene functions very well as a sensor for CRE/CREB-regulated transcription.

![Figure 6](image-url)

Figure 6. Pharmacological inhibition of CBP/p300 and BET bromodomain proteins attenuates TRPM3-induced activation of CREB. (A) Provirus containing the c-FosCRE^4.luc gene. The sequence
of the CRE is shown. (B) Domain structures of CREB, CREB2 and C2/CREB. KID, kinase inducible domain; Q1, Q2, glutamine-rich activation domains of CREB. (C) T-REx-TRPM3 cells were infected with a lentivirus encoding either C2/CREB or β-galactosidase (mock). Additionally, lentiviral gene transfer was used to integrate the c-FosCRE\(^4\).luc reporter gene into the chromatin. Infected T-REx-TRPM3 cells were maintained for 3 days. Cell extracts were prepared, luciferase activities were determined and protein concentrations were measured. The protein concentration were used to normalize the luciferase activities (\(n = 4; *** p < 0.001\)). (D, E) T-REx-TRPM3 cells containing a chromatin-embedded c-FosCRE\(^4\).luc reporter gene were maintained in serum-reduced and tetracycline-supplemented medium for 24 h. Stimulation was performed with pregnenolone sulfate for 24 h. Addition of either A485 (3 \(\mu\)M) (D) or JQ1 (0.5 \(\mu\)M) (E) to the culture medium is indicated. T-REx-TRPM3 cells were harvested and analyzed as described in the legend to Figure 2 (\(n = 3; ** p < 0.01; *** p < 0.001\)).

2.6. CBP/p300 and BET Proteins Control the Activation of CREB-Regulated Gene Transcription in Stimulated T-REx-TRPM3 Cells

We next analyzed whether stimulation of TRPM3 channels leads to increased transcription of the CRE-containing c-FosCRE\(^4\).luc reporter gene. Figure 6D,E show that stimulation of TRPM3 channels induced transcription of a CRE-containing reporter gene. This stimulation was impaired when we cultured the cells in the presence of A485 (Figure 6D) or JQ1 (Figure 6E). CRE-mediated transcription was reduced by more than 70% in the presence of the CBP/p300 inhibitor (Figure 6D), whereas incubation of the cells with the BET inhibitor JQ1 inhibited the CREB-regulated gene transcription by 87% (Figure 6E).

3. Discussion

Transcriptional activation by stimulus-responsive transcription factors requires access for these proteins to their DNA binding sites. DNA is embedded in a chromatin environment that may have an open or a compact configuration. Transcriptional co-regulators modify the chromatin structure and can act as a bridge between the basic transcriptional apparatus and DNA-bound transcription factors. In addition, the cofactors can cause specific local changes in the chromatin structure. These changes often include posttranscriptional modifications of histones, the proteins that form the core of the nucleosome. One important modification is the acetylation of histones, catalyzed by acetyltransferases. Hyperacetylation of histones is frequently observed in transcriptionally active genes. Acetylation of lysine residues reduces the positive charges of histone proteins, resulting in a lower affinity for acidic DNA and an altered nucleosomal structure. Histone acetylation thus facilitates transcription factors access to their DNA binding sites. Furthermore, several histone acetyltransferases interact with RNA polymerase II or with proteins of the basic transcriptional apparatus, establishing a causal link between histone acetylation and transcriptional activation [8,9]. Stimulation of TRPM3 Ca\(^{2+}\) channels activate transcription mediated by AP-1, c-Fos, c-Jun, Egr-1, and Elk-1. In this study, we investigated whether the activity of transcriptional coactivators and modifications of the chromatin structure are essential for TRPM3-mediated transcription.

Two of the most promiscuous acetyltransferases are the proteins CBP and p300. Both proteins interact with numerous transcriptional activator proteins such as CREB, p53, c-Jun, nuclear hormone receptors, NF-κB and others [13–15]. These interactions regulate biological functions such as cellular growth, proliferation, apoptosis, senescence, and differentiation. CBP/p300 proteins are acetyltransferases and their enzymatic activity contributes to chromatin-mediated transcriptional activation [15,21,22]. CBP/p300 proteins are considered global transcriptional co-activators that acetylate lysine residues in histones H2A, H2B, H3 (in particular H3K18, H3K27, and H3K56), and H4, and in non-histone proteins such as p53. In addition, CBP and p300 have been shown to promote the recruitment of RNAase polymerase II to enhancers, indicating that CBP/p300-catalyzed acetylation is essential for transcriptional initiation of enhancer-controlled gene transcription [23].

To selectively inhibit CBP/p300 activity, we used the potent and selective CBP/p300 catalytic inhibitor A485, a spirooxazolidinedione derivative. In contrast, the often-used
compound C646 showed off-target inhibitory effects [24]. A quantitative acetylomics study showed that treatment of cells with A485 reduced the acetylation pattern at approximately 1000 acetyl-lysine sites [25]. The co-crystal structure of the p300 catalytic active site together with the A485 molecule showed that A485 competes with acetyl-CoA. A485 did not inhibit the activities of histone acetyltransferases such as PCAF and others [26]. Functional assays revealed that this compound inhibited tumor growth [27,28]. The results of this study showed that incubation of cells with the compound A485 significantly decreased the activation of AP-1 in stimulated T-REx-TRPM3 cells, indicating that CBP/p300 proteins are involved in the signaling cascade linking TRPM3 Ca\(^{2+}\) channels to transcription of AP-1-responsive genes. Recently, the expression of the cytokine interleukin-8 was shown to be regulated by AP-1 [7]. Accordingly, TRPM3-induced activation of the IL-8 promoter was reduced in the presence of the CBP/p300 inhibitor A485. These results are in agreement with the observation that pro-inflammatory gene expression was inhibited by the p300 inhibitor C646 [28]. Moreover, in this study, we demonstrated for the first time that TRPM3 stimulation activates CREB and that this activation also requires CBP/p300. Finally, analysis of the transcriptional activation potential of c-Fos and Elk-1 revealed that upregulation of the transcriptional activities of these transcription factors requires CBP/p300. This study supports previous investigations showing that stimulus-activated transcription of target genes involving AP-1, CREB, or Elk-1 requires CBP and/or p300 activity [19,29].

While histone acetyltransferases are considered “writers” of posttranslational histone modifications, bromodomain-containing proteins are “readers” that bind to acetylated histone molecules [11]. Bromodomains are folding units comprising approximately 110 amino acids that are found in 46 human proteins that recognize acetylated lysine residues via a central hydrophobic pocket. Bromodomain inhibitors form hydrogen bonds with a conserved asparagine residue of the BET bromodomain, disrupting the interaction between acetylated lysines and BET bromodomains. By this means, the binding mode of acetyl-lysine is mimicked. CBP and p300 belong to the bromodomain proteins, as shown in Figure 1A. Acetylation of lysine residues of histone proteins is catalyzed by CBP and p300, thus creating binding sites for their bromodomain, which can stabilize chromatin interaction via a positive feedback loop. The BET proteins, which include BRD2, BRD3, BRD4, and testis-specific BRDT, are involved in the regulation of epigenetic gene transcription by regulating chromatin opening, recruitment of transcription factors, and co-activators. While BET proteins have been shown to be involved in transcriptional control, the role of bromodomains in other bromodomain proteins in regulating gene transcription has not been clearly defined [30]. Experiments with I-CBP112, a CBP/p300 bromodomain inhibitor, showed that this compound has only marginal effects on gene transcription [31]. To assess the importance of bromodomain-containing proteins in regulating transcription after stimulation of TRPM3 channels, we chose the highly potent and selective pan-BET inhibitor JQ1. This compound has a rather weak binding activity to CBP/p300, but binds competitively to bromodomains of all BET proteins [18,32]. Treatment with JQ1 displaces BET proteins from nuclear chromatin and thus regulates the expression of numerous target genes, including P-TEFb [18,33].

The results of this study showed that inhibition of bromodomain binding to acetylated lysine attenuated TRPM3-mediated activation of the transcription factors AP-1 and CREB. Moreover, TRPM3-induced activation of interleukin-8 expression was attenuated by the pan-BET inhibitor JQ1, supporting the view that BET proteins regulate inflammatory cytokine gene transcription [34,35]. Our data complement a study investigating the role of bromodomain proteins in endothelial cell inflammation [36], showing that treatment with JQ1 caused a reduction in interleukin-8 mRNA and protein levels. We also demonstrated that the biological activity of c-Fos and Elk-1 in TRPM3-stimulated cells was attenuated in the presence of JQ1. Thus, we have identified for the first time bromodomain proteins as regulators of TRPM3-induced gene transcription.

Our results showed that stimulation of TRPM3 channels activated gene transcription involving CBP/p300 and BET proteins. TRPM3 stimulation triggers an influx of Ca\(^{2+}\)
ions into the cells and activation of the protein kinase ERK1/2. An interesting question is whether the signaling cascade has an impact on the epigenetic regulation of transcription via post-translational modifications of epigenetic regulators. These regulators, like stimulus-responsive transcription factors, could act as an interface between extracellular signals and the transcription of selected genes. CBP is a substrate for protein kinases. In addition, activation of ERK1/2 and CaMKIV has been shown to be important in triggering neural activity-mediated gene transcription via NMDA receptors [37]. Two stimulus-responsive transcriptional activation domains have been identified in the CBP molecule [38]. Therefore, we hypothesize that different stimuli that trigger a similar signaling cascade in the cell may lead to similar activation of CBP/p300. The regulation of BET proteins by phosphorylation remains relatively unexplored. The BET protein BRD4 is a phosphoprotein and phosphorylation may be regulated by IL-6/IL-8-induced signaling [39]. However, the binding of BET proteins to acetylated lysine residues may be sufficient to induce their biological activities. With the specific compounds A485 and JQ1 at hand, future studies may elucidate the link between cellular stimulation and epigenetic regulation via CBP/p300 and BET proteins.

4. Materials and Methods
4.1. Cell Culture and Reagents

HEK293 cells containing the human TRPM3 coding region under the control of a tetracycline-responsive promoter (T-REx-TRPM3 cells) were kindly provided by David Beech and Yasser Majeed, University of Leeds, Leeds, UK, and cultured as described [40]. TRPM3 expression was induced by adding tetracycline (1 µg/mL, Sigma-Aldrich #T7680, dissolved in water) to the culture medium containing 0.05% fetal bovine serum for 24 h prior to the stimulation with pregnenolone sulfate (PubChem CID: 105074). Stimulation with pregnenolone sulfate (20 µM, Sigma #P162, dissolved in DMSO) was performed for 24 h in DMEM containing 0.05% fetal bovine serum. The selective CBP/p300 inhibitor A485 (A485: PubChem ID 118958122).

\[(1R)-N-[(4-Fluorophenyl)methyl]-2,3-dihydro-5-[(methylamino)carbonyl]amino]-\(2',4'\)-dioxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]spiro[1H-indene-1,5'-oxazolidine]-3'-acetamide\] was purchased from Tocris (Bristol, UK, #6387), dissolved in DMSO and used at a final concentration of 3 µM. The BET bromodomain inhibitor JQ1 (PubChem ID 46907787),(6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno [3,2-f][1,2,4]triazolo [4,3-α][1,4]diazipine-6-acetic acid 1,1-dimethylethyl ester) was purchased from Adooq Bioscience (Irvine, CA, USA, #A12729), dissolved in DMSO and used at a final concentration of 0.5 µM. The chemical structures of A485 and JQ1 are depicted in Figure 1B,D, respectively.

4.2. Lentiviral Gene Transfer

The lentiviral transfer vectors pFUW-C2/CREB, pFUW-GAL4-c-Fos, and pFUW-GAL4-Elk-1 have been described elsewhere [41,42]. The viral particles were produced by triple transfection of HEK293-TN cells with the packing plasmid pCMVΔR8.91 (5 µg/plate), plasmid pCMV-G (2.3 µg/plate) encoding the vesicular stomatitis virus glycoprotein, and the lentiviral transfer vector (6.6 µg/plate) using the calcium phosphate transfection method as described [2]. Cells were incubated overnight with the calcium phosphate-DNA precipitate in the presence of chloroquine (25 µM). Cells were washed the next day with phosphate-buffered saline and maintained for 72 h in DMEM medium containing 10% serum. Viral supernatants were harvested, centrifuged, and filtered through a 0.45 µM filter. Final viral stocks were supplemented with polybrene at a final concentration of 8 µg/mL.

4.3. Reporter Assays

The lentiviral transfer vectors pFWColl.luc, pFWIL-8.luc, pFWUAS5Sp12.luc, and pFWc-FosCRE4.luc have been described elsewhere [7,16,42]. T-REx-TRPM3 cells were infected with recombinant lentiviruses containing promoter/luciferase reporter genes. Following stimulation, cell extracts were prepared using reporter lysis buffer (Promega, Mannheim, Germany) and analyzed for luciferase activities. Luciferase activities of the
The present study provides evidence that epigenetic modulators are required in addition to the sequence-specific binding of transcription factors to DNA. CBP/p300 are histone acetylases that acylate lysine residues of histones and in this way induce an open chromatin structure. Our pharmacological analysis revealed that the coactivators CBP and p300 are essential for connecting TRPM3 stimulation with gene transcription. Acetylated lysine residues function as recognition motives for epigenetic BET proteins that further regulate epigenetic-controlled transcription via the recruitment of transcription factors, co-activators, and chromatin-organizing proteins. The fact that inhibition of BET protein interaction with acetyl-lysine residues attenuates TRPM3-mediated gene transcription indicates that BET proteins are important epigenetic regulatory proteins of TRPM3-mediated transcription. Based on these data, we propose a chromatin-based signaling cascade, involving DNA-bound stimulus-responsive transcription factors, recruitment of CBP/p300, acetylation of histones, and subsequent recruitment of the BET proteins to the transcription unit (Figure 7). Future studies will show whether the regulation of other biological functions of TRPM3 also requires CBP/p300 and BET proteins.

Figure 7. Regulation of epigenetic gene transcription by CBP/p300 and BET bromodomain proteins.

Transcription factors such as CREB and AP-1 bind to specific DNA binding sites and recruit the coactivator and histone acetyltransferase proteins CBP and p300. These proteins catalyze the acetylation of histones, and by this means generate an open chromatin architecture. CBP/p300 also acts as a bridge to the basal transcriptional apparatus to support transcriptional activation. BET proteins bind to acetylated lysine residues in histone proteins and recruit coactivators and epigenetic regulators required for transcription.
Author Contributions: Conceptualization, G.T.; methodology, G.T.; software, O.G.R.; validation, G.T. and O.G.R.; formal analysis, O.G.R.; investigation, G.T.; resources, G.T.; writing—original draft preparation, G.T.; writing—review and editing, G.T. and O.G.R.; visualization, O.G.R.; project administration, G.T.; funding acquisition, G.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the University of Saarland, grant number LOM-T201000492.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Acknowledgments: We thank David Beech and Yasser Majeed for proving T-REx-TRPM3 cells, Sabine Plant for excellent technical support, and Libby Guethlein for critical reading of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wagner, T.F.J.; Loch, S.; Lambert, S.; Straub, I.; Mannebach, S.; Mathar, I.; Düfer, M.; Lis, A.; Flockerzi, V.; Philipp, S.E.; et al. Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. *Nat. Cell Biol.* 2008, 10, 1421–1430. [CrossRef] [PubMed]
2. Lesch, A.; Rubil, S.; Thiel, G. Activation and inhibition of transient receptor potential TRPM3-induced gene transcription. *Br. J. Pharmacol.* 2014, 171, 2645–2658. [CrossRef] [PubMed]
3. Thiel, G.; Rubil, S.; Lesch, A.; Guethlein, L.A.; Rösller, O.G. Transient receptor potential TRPM3 channels: Pharmacology, signaling, and biological functions. *Pharmacol. Res.* 2017, 124, 92–99. [CrossRef] [PubMed]
4. Vriens, J.; Owsianik, G.; Hofmann, T.; Philipp, S.E.; Stab, J.; Chen, X.; Benoit, M.; Xue, F.; Janssens, A.; Kerselaers, S.; et al. TRPM3 is a nociceptor channel involved in the detection of noxious heat. *Neuron* 2011, 70, 482–494. [CrossRef]
5. Vandewauw, I.; De Clercq, K.; Mulier, M.; Held, K.; Pinto, S.; Van Ranst, N.; Segal, A.; Voet, T.; Vennekens, R.; Zimmermann, K.; et al. A TRP channel trio mediates acute noxious heat sensing. *Nature* 2018, 555, 662–666. [CrossRef]
6. Lesch, A.; Hui, X.; Lipp, P.; Thiel, G. Transient receptor potential metastatin-3 (TRPM3)-induced activation of AP-1 requires Ca2+ ions and the transcription factors c-Jun, ATF2, and ternary complex factor. *Mol. Pharmacol.* 2015, 87, 617–628. [CrossRef]
7. Rubil, S.; Lesch, A.; Mukaida, N.; Thiel, G. Stimulation of transient receptor potential M3 channel increases interleukin-8 gene promoter activity involving AP-1 and extracellular signal-regulated protein kinase. *Cytokine* 2013, 103, 133–141. [CrossRef]
8. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. *Genes Dev.* 1998, 12, 599–606. [CrossRef]
9. Shvedunova, M.; Akhtar, A. Modulation of cellular processes by histone and non-histone protein acetylation. *Nat. Rev. Mol. Cell Biol.* 2022, 23, 329–349. [CrossRef]
10. Nitsch, S.; Zorro Shahidian, L.; Schneider, R. Histone acetylation and chromatin dynamics: Concepts, challenges, and links to metabolism. *EMBO Rep.* 2021, 22, e52774. [CrossRef]
11. Filippakopoulos, P.; Knapp, S. Targeting bromodomodomains: Epigenetic readers of lysine acetylation. *Nat. Rev. Drug Discov.* 2014, 13, 337–356. [CrossRef] [PubMed]
12. Gekani, S.; Kumar Bhatt, L. Bromodomains: A novel target for the anticancer therapy. *Eur. J. Pharmacol.* 2021, 911, 174523. [CrossRef] [PubMed]
13. Vo, N.; Goodman, R.H. CREB-binding protein and p300 in transcriptional regulation. *J. Biol. Chem.* 2001, 276, 13505–13508. [CrossRef]
14. Wang, F.; Marshall, C.B.; Ikura, M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: Structural and functional versatility in target recognition. *Cell. Mol. Life Sci.* 2013, 70, 3989–4008. [CrossRef]
15. Dancy, B.M.; Cole, P.A. Protein lysine acetylation by p300/CBP. *Chem. Rev.* 2015, 115, 2419–2452. [CrossRef] [PubMed]
16. Thiel, G.; Backes, T.M.; Guethlein, L.A.; Rösller, O.G. Chromatin-embedded reporter genes: Quantification of stimulus-induced gene transcription. *Gene* 2021, 787, 145645. [CrossRef]
17. Majeed, Y.; Agarwal, A.K.; Naylor, J.; Seymour, V.A.L.; Jiang, S.; Muraki, K.; Fishwick, C.W.; Beech, D.J. Cis-isomerism and other chemical requirements of steroid agonists and partial agonists acting at TRPM3 channels. *Br. J. Pharmacol.* 2010, 161, 430–441. [CrossRef]
18. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I.; et al. Selective inhibition of BET bromodomains. *Nature* 2010, 468, 1067–1073. [CrossRef]
19. Kwok, R.P.; Lundblad, J.R.; Chrvia, J.C.; Richards, J.P.; Bächinger, H.P.; Brennan, R.G.; Roberts, S.G.; Green, M.R.; Goodman, R.H. Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* 1994, 370, 223–226. [CrossRef]
20. Lundblad, J.R.; Kwok, R.P.S.; Laurence, M.E.; Harter, M.L.; Goodman, R.H. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. *Nature* 1995, 374, 85–88. [CrossRef]
21. Ogryzko, V.V.; Schiltz, R.L.; Russanova, V.; Howard, B.H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 1996, 87, 953–959. [CrossRef]
22. Martinez-Balbas, M.A.; Bannister, A.J.; Martin, K.; Haus-Seuffert, P.; Meisterernst, M.; Kouzarides, T. The acetyltransferase activity of CBP stimulates transcription. *EMBO J.* 1998, 17, 2886–2893. [CrossRef]

23. Narita, T.; Ito, S.; Higashijima, Y.; Chu, W.K.; Neumann, K.; Walter, J.; Satpathy, S.; Liebner, T.; Hamilton, W.B.; Maskey, E.; et al. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAIIP recruitment, and pause release. *Mol. Cell* 2021, 81, 2166–2182. [CrossRef] [PubMed]

24. Dahlin, J.L.; Nelson, K.M.; Strasser, J.M.; Barsyte-Lovejoy, D.; Szewczyk, M.M.; Organ, S.; Cuellar, M.; Singh, G.; Shrimp, J.H.; Nguyen, N.; et al. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. *Nat. Commun.* 2017, 8, 1527. [CrossRef]

25. Weinert, B.T.; Narita, T.; Satpathy, S.; Srinivasan, B.; Hansen, B.K.; Schölz, C.; Hamilton, W.B.; Zucconi, B.E.; Wang, W.W.; Liu, W.R.; et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. *Cell* 2018, 174, 231–244. [CrossRef] [PubMed]

26. Lasko, L.M.; Jakob, C.G.; Edalji, R.P.; Qiu, W.; Montgomery, D.; Digiammario, E.L.; Hansen, T.M.; Risi, R.M.; Frey, R.; Manaves, V.; et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* 2017, 550, 128–132. [CrossRef] [PubMed]

27. Zhang, X.; Zegar, T.; Lucas, A.; Morrison-Smith, C.; Knox, T.; Knapp, S.; Müller, S.; Siveke, J.T. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. *Oncogene* 2020, 39, 4770–4779. [CrossRef] [PubMed]

28. Van den Bosch, T.; Boichenko, A.; Leus, N.G.J.; Ouralilidou, M.E.; Wapenaar, H.; Rotili, D.; Mai, A.; Imhof, A.; Bischoff, R.; Haisma, H.J.; et al. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. *Biochem. Pharmacol.* 2016, 102, 130–140. [CrossRef]

29. Li, Q.-J.; Yang, S.-H.; Maeda, Y.; Sladek, F.M.; Sharrocks, A.D.; Martins-Green, M. MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. *EMBO J.* 2003, 22, 281–291. [CrossRef]

30. Picaud, S.; Leonards, K.; Lambert, J.-P.; Dovey, O.; Wells, C.; Fedorov, O.; Monteiro, O.; Fujisawa, T.; Wang, C.-Y.; Lingard, H.; et al. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulator of primary transcription response in leukemia. *Sci. Adv.* 2016, 2, e1600760. [CrossRef]

31. Zucconi, B.E.; Makofskie, J.I.; Meyers, D.J.; Hwang, Y.; Wu, M.; Kuroda, M.I.; Cole, P.A. Combination targeting of the bromodomain and acetyltransferase active site of p300/CBP. *Biochemistry* 2019, 58, 2133–2143. [CrossRef]

32. Picaud, S.; Fedorov, O.; Thanasopoulos, A.; Leonardis, K.; Jones, K.; Meier, J.; Olzscha, H.; Monteiro, O.; Martin, S.; Philpott, M.; et al. Generation of a selective small inhibitor of the CBP/p300 bromodomain for leukemia therapy. *Cancer Res.* 2015, 75, 5106–5119. [CrossRef]

33. Decker, T.-M.; Kluge, M.; Krebs, S.; Shah, N.; Blum, H.; Friedel, C.C.; Eick, D. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1. *Sci. Rep.* 2017, 7, 1684. [CrossRef] [PubMed]

34. Belkina, A.C.; Nikolajczyk, B.S.; Denis, G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. *J. Immunol.* 2013, 190, 3670–3678. [CrossRef]

35. Shi, X.; Liu, C.; Liu, B.; Chen, J.; Wu, X.; Gong, W. JQ1: A novel potential therapeutic target. *Pharmazie* 2018, 73, 491–493. [PubMed]

36. Mumba, S.; Gambaryan, N.; Meng, C.; Perros, F.; Humbert, M.; Wort, S.J.; Adcock, I.M. Bromodomain and extra-terminal domain protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. *Respirology* 2017, 22, 157–164. [PubMed]

37. Impney, S.; Fong, A.L.; Wang, Y.; Cardinaux, J.-R.; Fass, D.M.; Obrietan, K.; Wayman, G.A.; Storm, D.R.; Soderling, T.R.; Goodman, R.H. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. *Neuron* 2002, 34, 235–244. [CrossRef]

38. Hu, S.-C.; Chrivia, J.; Ghosh, A. Regulation of CBP-mediated transcription by neuronal calcium signaling. *Neuron* 1999, 22, 799–808. [CrossRef]

39. Wang, W.; Tang, Y.-A.; Xiao, Q.; Lee, W.C.; Cheng, B.; Niu, Z.; Oguz, G.; Feng, M.; Lee, P.L.; Li, B.; et al. Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal cancer. *Nat. Commun.* 2021, 12, 4441. [CrossRef] [PubMed]

40. Naylor, J.; Milligan, C.J.; Zeng, F.; Jones, C.; Beech, D.J. Production of a specific extracellular inhibitor of TRPM3 channels. *Br. J. Pharmacol.* 2008, 155, 567–573. [CrossRef] [PubMed]

41. Thiel, G.; Rössler, O.G. Immediate-early transcriptional response to angiotensin II in human adrenocortical cells. *Endocrinology* 2011, 152, 4211–4223. [CrossRef] [PubMed]

42. Thiel, G.; Rössler, O.G. Resveratrol stimulates cyclic AMP response element-mediated gene transcription. *Mol. Nutr. Food Res.* 2016, 60, 256–265. [CrossRef] [PubMed]